产品封面图

F10 / Factor X Antibody

收藏
  • ¥495
  • Leading Biology
  • 2025年07月11日
  • WB, IHC-P, E
  • Sheep
  • Human
avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 保存条件

      Store at +4°C short term. For long-term storage, aliquot and store at -20°C or below. Stable for 12 months at -20°C. Avoid repeated freeze-thaw cycles.

    • 适应物种

      Human

    • 库存

      100

    • 宿主

      Sheep

    • 应用范围

      WB, IHC-P, E

    • 靶点

      Recognizes human Factor X.

    • 规格

      50 μg

    Prouduct: We constantly strive to ensure we provide our customers with the best antibodies. As a result of this work we offer this antibody in purified format. We are in the process of updating our datasheets. If you have any questions regarding this update, please feel free to contact our technical support team. This product is a high quality F10 / Factor X Antibody. Functiong: Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting. Summary: Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验
    • Notes on Making Rat x Y3 Monoclonal Antibody Producing Hybridomas

      Although Y3/Ag1.2.3 has its own myeloma light chain, their are numerous characteristics that make this a better parent line for making hybridomas than the 'Y0' chain loss variants or using NS0 to make rat x mouse hybrids. These are: a) Hybridomas

    • Rat x Rat Hybridomas

      There is an increasing interest in the preparation of rat � rat hybridomas, because they have been found to be more stable in culture than mouse hybridomas and they secrete consistently high levels (10 �g/mL and above) of monoclonal antibody

    • Gene Therapy of X-Linked Severe Combined Immunodeficiency

      This review describes the main steps which led to carrying out the gene ther-apy clinical trial for Xlinked severe combined immune deficiency (SCID-X1) patients, from the preparation of the retroviral vector up to the design of GMP conditions

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    武汉佰瑞得生物技术有限公司
    2025年07月12日询价
    ¥5000
    GeneTex
    2025年07月09日询价
    ¥495
    安诺伦(北京)生物科技有限公司
    2023年10月25日询价
    ¥5000
    深圳欣博盛生物科技有限公司
    2025年05月11日询价
    F10 / Factor X Antibody
    ¥495